Somavert Related Published Studies
Well-designed clinical trials related to Somavert (Pegvisomant)
Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. [2006.08]
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. [2005.10]
High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization. [2004.02]
A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. [2002.04]
Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. [2002.04]
Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency. [2001.11]
Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion. [2001.10]
Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. [2001.07]
Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. [2001.07]
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. [2000.04.20]
Well-designed clinical trials possibly related to Somavert (Pegvisomant)
The effects of GH and hormone replacement therapy on serum concentrations of mannan-binding lectin, surfactant protein D and vitamin D binding protein in Turner syndrome. [2004.03]
The effects of a specific growth hormone antagonist on overnight insulin requirements and insulin sensitivity in young adults with Type 1 diabetes mellitus. [2003.09]
Lessons from 6 years of GH receptor antagonist therapy for acromegaly. [2003]
Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. [2002.12]
Effects of a growth hormone receptor antagonist on bone markers in acromegaly. [2002.09]
GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-I independent immunomodulatory effect of GH. [2001.11]
Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. [2000.08]
Other research related to Somavert (Pegvisomant)
Lipodystrophy in patients with acromegaly receiving pegvisomant. [2008.09]
Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. [2008.08]
Long-term effects of pegvisomant in patients with acromegaly. [2008.06]
The role of pegvisomant in the treatment of acromegaly. [2008.05]
Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study. [2008.04]
Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. [2007.12]
Concomitant, specific determination of growth hormone and pegvisomant in human serum. [2007.10]
Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. [2007.09]
[Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly] [2007.09]
Discovery and uses of pegvisomant: a growth hormone antagonist. [2007.07]
The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. [2007.05]
Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma. [2007.03]
Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. [2007.02.01]
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. [2007.01]
Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. [2007.01]
Experience from the German pegvisomant observational study. [2007]
Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy. [2007]
Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. [2007]
McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. [2006.12]
IVF/ICSI in a woman with active acromegaly: successful outcome following treatment with pegvisomant. [2006.11]
Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly. [2006.11]
An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant. [2006.06]
Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. [2006.06]
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. [2006.03]
Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. [2006.02]
Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1. [2006]
Nanomedicines in the treatment of acromegaly: focus on pegvisomant. [2006]
Pegvisomant Treatment in a 4-Year-Old Girl with Neurofibromatosis Type 1. [2005.11.01]
Treatment of pituitary tumors: pegvisomant. [2005.10]
Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. [2005.08]
Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. [2005.08]
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. [2005.05.07]
Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. [2005.03]
Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant. [2005.01]
The place of pegvisomant in the acromegaly treatment algorithm. [2004.06]
Pegvisomant Pfizer/Sensus. [2004.04]
Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly. [2004.03]
Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. [2003.12]
Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. [2003.12]
Pegvisomant in the treatment of acromegaly. [2003.09.26]
The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly. [2003.08]
Pegvisomant: an advance in clinical efficacy in acromegaly. [2003.04]
Clinical use of pegvisomant for the treatment of acromegaly. [2003]
Pegvisomant. Pharmacia. [2002.05]
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. [2001.11.24]
The place of pegvisomant in the management of acromegaly. [2001.09]
Experience with pegvisomant in the treatment of acromegaly. [2001.06]
Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. [2001.02]
Pegvisomant: a growth hormone receptor antagonist for the treatment of acromegaly. [2000.04]
Other possibly related research studies
Treatment of acromegaly: future. [2005.10]
Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. [2005.10]
Effects of medical therapy on pituitary tumors. [2005.05]
Optimizing somatostatin analog therapy in acromegaly: long-acting formulations. [2002]
Diagnosis and treatment of pituitary adenomas. [2004.12]
New therapeutic options for acromegaly. [2004.12]
The challenges of reliance on insulin-like growth factor I in monitoring disease activity in patients with acromegaly. [2004]
Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. [2004.11]
GH receptor antagonist: mechanism of action and clinical utility. [2005.01]
Treatment of acromegaly. [2004]
Insights from growth hormone receptor blockade. [2004.10]
The role of growth hormone-receptor antagonism in relation to acromegaly. [2004.11]
The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs. [2003]
Pharmacological approach to the treatment of acromegaly. [2004.04.15]
Medical treatment in acromegaly. [2003.12]
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. [2003.10]
Metabolic effects of GH antagonism in patients with acromegaly. [2003.08]
How effective are current therapies for acromegaly? [2003.08]
Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. [2003.04]
Primary medical therapy for acromegaly. [2003.04]
Growth hormone receptor antagonists. [2002.12]
The future of growth hormone antagonists. [2002.12]
Role of hormones in the pathogenesis and management of sarcopenia. [2002]
Growth hormone receptor antagonist improves insulin resistance in acromegaly. [2002.12]
Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. [2002.10]
Acromegaly: a new therapy. [2002.05]
Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. [2002.03]
Ghrelin drives GH secretion during fasting in man. [2002.02]
[Therapy of pituitary diseases. What can be achieved with medication and hormones?] [2001.11.01]
Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. [2001.11]
Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. [2001.10]
Findings and theoretical considerations on the usefulness of the acid-labile subunit in the monitoring of acromegaly. [2001.06]
[Growth hormone receptor antagonists: potential indications] [2001.01.13]
Responsiveness of irradiated rat anterior pituitary cells to hypothalamic releasing hormones is restored by treatment with growth hormone. [2000.12]
Growth hormone receptor antagonists therapy for acromegaly. [1999.10]
|
